AN ADHERENT CELL MODEL TO STUDY DIFFERENT STAGES OF APOPTOSIS

被引:77
作者
DESJARDINS, LM
MACMANUS, JP
机构
[1] Apoptosis Research Group, Institute for Biological Sciences, National Research Council of Canada, Ottawa
关键词
D O I
10.1006/excr.1995.1048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Apoptosis in the classical thymocyte model occurs very rapidly making it difficult to study the intermediate steps in the process, An alternative adherent cell model is characterized and proposed in this paper, HT29 cells treated with a teniposide were collected at various times for morphological and biochemical assessments, Large DNA breaks (450-500, 350-400, 100-200 kb) were observed in these cells between 6 and 24 h, The larger DNA breaks appeared initially and in progression such that the smaller DNA break of 100-200 kb became apparent by 24 h. These changes in DNA corresponded with an increase in cell diameter and a gradual rounding and detaching of cells from each other but not from the tissue culture plates, The smallest DNA break of 23-50 kb appeared at 48 h and persisted throughout the 96 h of incubation. DNA ladders of 180- to 200-bp oligomers were also observed between 48 and 96 h and these coincided with the presence of small floating cells. Changes in cell adherence after teniposide treatment have permitted the consistent isolation of cells in four distinct morphological and biochemical stages of apoptosis: (1) ''preapoptotic,'' (2) ''swelling,'' (3) ''rounding,'' and (4) ''floating.'' The main advantages of this adherent cell model are: (1) apoptosis occurs very slowly (minimum of 48 h) permitting the observation of progressive changes; (2) cells from four stages of apoptosis can be used to study the sequence of events of other biochemical and genetic factors involved in the process; and (3) extracellular matrix proteins are present in this model so their participation in apoptosis, if any, can be determined. (C) 1995 Academic Press, Inc.
引用
收藏
页码:380 / 387
页数:8
相关论文
共 25 条
  • [1] ACTIVATION OF PROGRAMMED CELL-DEATH (APOPTOSIS) BY CISPLATIN, OTHER ANTICANCER DRUGS, TOXINS AND HYPERTHERMIA
    BARRY, MA
    BEHNKE, CA
    EASTMAN, A
    [J]. BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) : 2353 - 2362
  • [2] BERTRAND R, 1991, CANCER RES, V51, P6280
  • [3] BROWN DG, 1993, J BIOL CHEM, V268, P3037
  • [4] COHEN GM, 1993, J IMMUNOL, V151, P1
  • [5] APOPTOSIS AND PROGRAMMED CELL-DEATH IN IMMUNITY
    COHEN, JJ
    DUKE, RC
    FADOK, VA
    SELLINS, KS
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1992, 10 : 267 - 293
  • [6] COMPTON MM, 1992, TRENDS ENDOCRIN MET, P17
  • [7] EVANS DL, 1993, CANCER RES, V53, P2133
  • [8] Fogh J., 1975, HUMAN TUMOR CELLS IN, P115
  • [9] IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION
    GAVRIELI, Y
    SHERMAN, Y
    BENSASSON, SA
    [J]. JOURNAL OF CELL BIOLOGY, 1992, 119 (03) : 493 - 501
  • [10] GEWIRTZ DA, 1993, CANCER RES, V53, P3547